key: cord-0852741-s75yb867 authors: Piros, Éva Anna; Cseprekál, Orsolya; Görög, Anna; Hidvégi, Bernadett; Medvecz, Márta; Szabó, Zsófia; Olajos, Ferenc; Barabás, Eszter; Galajda, Noémi; Miheller, Pál; Holló, Péter title: Seroconversion after anti‐SARS‐CoV‐2 mRNA vaccinations among moderate‐to‐severe psoriatic patients receiving systemic biologicals—Prospective observational cohort study date: 2022-03-05 journal: Dermatol Ther DOI: 10.1111/dth.15408 sha: 7b8299d50d8dc32bfb747f3cdeaf269abc1d3365 doc_id: 852741 cord_uid: s75yb867 It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)‐based antisevere acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) vaccinations. To assess antibody formation and the incidence of side effects after anti‐SARS‐CoV‐2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls. 102 moderate‐to‐severe psoriatic patients (56.2 [±13.5] years) and 55 age‐matched healthy (56.4 ± 13.6 years) volunteers were included in our study. Ten to 21 days after the administration of the second dosage of BNT162b2 or mRNA‐1273 vaccine, antibody levels specific to the SARS‐CoV‐2 spike (S) protein receptor binding domain were monitored. The incidence of postvaccination side effects was recorded and compared to real‐life data in the literature. Of the 102 patients, 57 (55.88%) received tumor necrosis factor (TNF), 28 (27.45%) received interleukin (IL)‐12/23, 16 (15.68%) received IL‐17, and 1 (0.99%) received IL‐23 inhibitors. No significant differences in the median serum level of anti‐SARS‐CoV‐2S antibody were observed between the study population and the control group (median IQR range: 1681.0 U/mL (600.0–4844.0) versus 1984.0 U/mL (1000.0–3136.0; p = 0.82). The most frequent side effects of the mRNA vaccines within 7 days after the administration of both dosages were arm pain on the side of injection (23.53% and 23.53%), fatigue (9.80% and 13.72%), headache (4.9% and 5.88%), and chills or shivering (4.9% and 8.82%). Detectable antibodies against SARS‐CoV‐2S protein appear 10–21 days after the administration of the second dosage of BNT162b2 or mRNA‐1273 vaccines in moderate‐to‐severe psoriatic patients receiving biologicals, similar to those of healthy controls. second dosage of BNT162b2 or mRNA-1273 vaccines in moderate-to-severe psoriatic patients receiving biologicals, similar to those of healthy controls. , and it has steadily progressed into a global pandemic. 1 A large amount of data is already available about comorbidities, which lead to a poor outcome of COVID-19. [2] [3] [4] Compared to the general population, psoriasis does not increase the risk of SARS-CoV-2 infection. 5, 6 However, psoriasis is often accompanied by several other comorbidities, such as metabolic syndrome and cardiovascular diseases, which on their own result in a poor COVID-19 outcome in the general population. 7 16 In this study, the authors' aim was to investigate anti-SARS-CoV-2S antibody levels after the administration of the second dose of the anti-Budapest, Hungary (approval number: IV/861-1/2021/EKU, date of approval: January 27, 2021) and meets all requirements of the Declaration of Helsinki. Patients provided written informed consent to participate and donate blood for the purpose of our study. This multicenter study investigated a prospective cohort of immuno- Patients were excluded if they had a polymerase chain reaction (PCR) proven current or previous SARS-CoV-2 infection, previous severe vaccination reaction (anaphylaxis), known primary immunodeficiency that affects adaptive immunity, status of splenectomy or functional asplenia, solid organ transplantation within 3 months, treatment targeting B-cell clones (anti-CD20), neutropenia (neutrophil granulocyte < 0.5 G/L), lymphopenia (lymphocyte count < 0.5 G/L), pregnancy or breast-feeding, or were planning to conceive a child within 2 months. Patients were also excluded if any of the following conditions were present: psoriatic disease for less than 6 months, induction period of the applied antipsoriatic systemic biological therapy, concomitant MTX therapy, or younger than 18 years. vaccination, 5 mL of blood samples were collected. Side effects were registered after both vaccinations. We examined the effects of these two vaccines together because the mechanism and efficacy are approximately the same. 18 , 19 We did not stratify the patients according to the type of mRNA vaccinations. Control group consisted of 55 volunteers who were, healthy agematched health care workers (45 women, 10 men) were enrolled in the study (age: 56.4 ± 13.6 years). The exclusion criteria were an autoimmune disease or positive SARS-CoV-2 antibody test results with the Roche test before vaccination. Specific antibody tests (Roche anti-SARS-CoV-2 S immunoassay) were used to examine the presence of antibodies 10-14 days after the administration of the second dose of mRNA vaccine. The incidence rates of side effects after the administration of both dosages of mRNA vaccines are shown in Table 2 . The results of the laboratory examinations are shown in Tables 3 and 4 and Figure 1 . History is repeating itself: probable zoonotic spillover as the cause of the 2019 novel coronavirus epidemic Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in new York City: a prospective cohort study Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes Epidemiology and outcomes of novel coronavirus 2019 in patients with immunemediated inflammatory diseases Covid-19 in immune-mediated inflammatory diseases -case series from New York Psoriasis, biological drugs and coronavirus disease 2019: real life experience of two Italian provinces Clinical determinants for fatality of 44,672 patients with COVID-19 Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments Advances in gene-based vaccine platforms to address the COVID-19 pandemic Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support The REDCap consortium: building an international community of software platform partners Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis Immune response to pneumococcus and tetanus toxoid in patients with moderate-tosevere psoriasis following long-term ustekinumab use Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab Secukinumab does not impair the immunogenic response to the influenza vaccine in patients Thromboembolic complications of SARS-CoV-2 and metabolic derangements: suggestions from clinical practice evidence to causative agents The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines (Basel) Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom Antibody response following a two-dose mRNA vaccination regimen, in Health Care Workers of a Tertiary Hospital in Athens, Greece Reactogenicity following receipt of mRNA-based COVID-19 vaccines The authors have no conflicts of interest to declare.The article has not been presented prior. Manuscript has not been previously published and is not currently submitted elsewhere. All the authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request for non-commercial purposes. https://orcid.org/0000-0001-7131-9682